Publications by authors named "V A Meledin"
Background: Aortic valve stenosis of any degree is associated with poor outcomes.
Objectives: The authors aimed to develop a risk prediction model for aortic stenosis (AS) prognosis using machine learning techniques.
Methods: A prognostic algorithm was developed using an AS registry of 10,407 patients undergoing echocardiography between 2008 and 2020.
Aims: Myocardial abnormalities are common during COVID-19 infection and recovery. We examined left (LV) and right (RV) ventricular longitudinal strain in patients who had recovered from COVID-19 and assessed the correlation with exercise capacity.
Methods And Results: One hundred and eighty-four consecutive patients with history of COVID-19 disease who had been referred to rest or stress echocardiography because of symptoms, mainly dyspnea and chest pain, were included in the study.
Aims: The aim of this study was to examine the prevalence of amyloid transthyretin (ATTR) cardiac amyloidosis in patients 1-2 years after trans-catheter aortic valve replacement (TAVR) and to assess their clinical and echocardiographic outcome and long-term survival.
Methods And Results: We enrolled 88 patients, mean age 81 years, 534 (390-711) days after TAVR. Patients underwent a Tc99m-PYP scintigraphy for the diagnosis of ATTR cardiac amyloidosis.
Article Synopsis
- This study aimed to analyze the inflammatory responses during transcatheter aortic valve implantation (TAVI) in patients with reduced left ventricular (LV) function compared to those with preserved LV function.
- 156 patients participated, showing that those with reduced LV function had a higher baseline neutrophil to lymphocyte ratio (NLR) than those with preserved LV function, but after six months, their inflammatory profiles became similar.
- The findings suggest that TAVI improves the inflammatory profile in patients with reduced LV function, contributing to the overall benefits of the procedure without significant long-term mortality differences between the two groups.
Aim: Transthyretin cardiac amyloidosis (ATTR-CA) is an increasingly recognized cause of heart failure (HF) with preserved left ventricular ejection fraction (LVEF), typically presenting as restrictive cardiomyopathy. The potential co-existence of ATTR-CA with systolic heart failure has not been studied. The aim of this study is to describe the prevalence of ATTR-CA and its clinical characteristics in HF patients with reduced LVEF.
View Article and Find Full Text PDF